公开(公告)号：EP3122190A2

公开(公告)日：2017-02-01

申请号：EP15769049.6

申请日：2015-03-25

申请人： Gutierrez, Enrique G.

发明人： Gutierrez, Enrique G.

IPC分类号： A01N47/34

CPC分类号： A61K33/24 ,  A61K9/0053 ,  A61K9/14 ,  A61K31/64 ,  A61K45/06 ,  A61K2300/00

摘要： Disclosed are pharmaceutical compositions and related methods for treating a subject with a viral or retroviral infection. The disclosed compositions and methods comprise and utilize an effective amount of one or more vanadium-containing compounds and an effective amount of one or more sulfonylureas. In certain embodiments, the viral infection is human immunodeficiency virus (HIV) and the compositions and methods improve one or more immunologic cellular parameters, such as viral load, CD4 counts and CD4/CD8 lymphocyte cell ratios in a subject. Also disclosed are methods of improving one or more immunologic cellular parameters that are associated with viral infections such as HIV in a subject, including viral load, CD4 counts and CD4/CD8 lymphocyte cell ratios.

摘要翻译： 本发明公开了药物组合物和用于治疗与病毒或逆转录病毒感染的受试者相关方法。 盘组合物游离缺失和方法包括在有效量的一种或多种含钒化合物和有效量的一种或多种磺酰脲的利用。 在某些实施方案中，所述病毒感染是人体免疫缺陷病毒（HIV）和所述组合物和方法改善一种或多种免疫细胞参数，颜色：例如病毒载量，CD4细胞计数和CD4 / CD8淋巴细胞比例的细胞在受试者中。 所以盘游离缺失是提高一个或多个免疫细胞参数也与病毒感染相关的方法：如在HIV的受试者，包括病毒载量，CD4细胞计数和CD4 / CD8淋巴细胞比例。

公开(公告)号：EP2619579B1

公开(公告)日：2016-12-07

申请号：EP11827399.4

申请日：2011-09-21

申请人： The General Hospital Corporation ,  Trustees of Boston University

发明人： STEERE, Allen C. ,  DROUIN, Elise ,  COSTELLO, Catherine ,  SEWARD, Robert

IPC分类号： G01N33/53 ,  G01N33/68 ,  G01N33/74 ,  G01N33/564

CPC分类号： G01N33/6863 ,  G01N33/564 ,  G01N33/74 ,  G01N2800/102 ,  Y02A50/57

摘要： The present invention provides for methods and compositions for identifying and detecting autoantigens. Candidate autoantigens are identified by obtaining a subject sample from which HLA-DR-presented peptides are collected and identified using mass spectometry, then synthesized and reacted with the same subject peripheral blood or effected tissue. In particular, the present invention provides for endothelial cell growth factor as a novel autoantigen biomarker for Lyme disease-associated arthritis.

摘要翻译： 本发明提供用于鉴定和检测自身抗原的方法和组合物。 通过获得候选的自身抗原，通过获得使用质谱法收集和鉴定HLA-DR呈递的肽的受试者样品来鉴定，然后合成并与相同受试者的外周血或有影响的组织反应。 特别地，本发明提供内皮细胞生长因子作为莱姆病关联性关节炎的新型自身抗原生物标志物。

公开(公告)号：EP2981247A1

公开(公告)日：2016-02-10

申请号：EP14723543.6

申请日：2014-03-13

申请人： Pulmatrix, Inc.

发明人： SUNG, Jean C. ,  MANZANEDO, Diana ,  PERRY, Jason M. ,  DEHAAN, Wesley, H. ,  TRAUTMAN, Brian

IPC分类号： A61K9/00 ,  A61K9/16 ,  A61K31/00

CPC分类号： A61K31/439 ,  A61K9/0075 ,  A61K9/1611 ,  A61K9/1617 ,  A61K31/57 ,  A61K31/58 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to respirable dry powder comprising respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is about 60% to about 90%, the leucine is about 10% to about 40%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. The invention also relates to respirable dry powders that contain respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is 67% to 84%, the leucine is 12% to 28%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. The invention also relates to respirable dry powders that contain respirable dry particles that comprise about 79.5% to about 80.5% (w/w) sodium chloride, about 19.5% to about 20.5% (w/w) leucine, and about 0.01% to about 0.5% (w/w) tiotropium bromide, and methods for treating a subject using the respirable dry powders.

摘要翻译： 本发明涉及包含氯化钠，亮氨酸和噻托溴铵的可呼吸干燥颗粒的可呼吸干粉，其中氯化钠为约60％至约90％，亮氨酸为约10％至约40％，噻托溴铵 约0.01％至约0.5％，以及任选的一种或多种额外的治疗剂至多约20％，其中所有百分比均为干基重量百分数，所有可呼吸干燥颗粒的组分均为100％。 本发明还涉及包含可氯化钠，亮氨酸和噻托溴铵的可呼吸干燥颗粒的可呼吸干粉，其中氯化钠为67％至84％，亮氨酸为12％至28％，噻托溴铵为约0.01 ％至约0.5％，以及任选的一种或多种额外的治疗剂至多约20％，其中所有百分比均为干基重量百分比，所有可呼吸干燥颗粒的组分均为100％。 本发明还涉及包含可吸入干颗粒的可呼吸干粉，其包含约79.5％至约80.5％（w / w）氯化钠，约19.5％至约20.5％（w / w）亮氨酸，和约0.01％至约 0.5％（w / w）噻托溴铵，以及使用可吸入干粉治疗受试者的方法。

公开(公告)号：EP2919799A1

公开(公告)日：2015-09-23

申请号：EP13855431.6

申请日：2013-03-25

申请人： The Walter and Eliza Hall Institute of Medical Research

发明人： HARRISON, Leonard Charles ,  RASHIDI, Maryam ,  ZHANG, Yuxia

IPC分类号： A61K38/10 ,  C12N15/12 ,  C12N15/86 ,  G01N33/15 ,  G01N33/50 ,  A61P37/06

CPC分类号： G01N33/6896 ,  A61K38/00 ,  C07K14/70592 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2893 ,  C07K2317/76 ,  C07K2319/30 ,  C12N5/0637 ,  G01N33/502 ,  G01N33/564 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2333/70592 ,  G01N2800/26 ,  G01N2800/285 ,  G01N2800/50 ,  G01N2800/52

摘要： The present disclosure relates to the use of a soluble CD52 glycoprotein in treating diseases regulated by effector T-cells, for example sepsis or multiple sclerosis. The present disclosure also relates to diagnostic methods based on the detection of CD52 expression levels in a subject.

摘要翻译： 本公开涉及可溶性CD52糖蛋白在治疗由效应T细胞调节的疾病中的用途，所述疾病例如脓毒症或多发性硬化症。 本公开还涉及基于检测受试者中的CD52表达水平的诊断方法。

公开(公告)号：EP2697066B1

公开(公告)日：2014-12-24

申请号：EP12754071.4

申请日：2012-08-06

申请人： GEW (EC) Limited

发明人： RAE, Malcolm ,  HICKS, James

IPC分类号： B41F23/04

CPC分类号： B41J11/0015 ,  B41F23/04 ,  B41F23/0409 ,  B41F23/0483

公开(公告)号：EP2799104A1

公开(公告)日：2014-11-05

申请号：EP14166563.8

申请日：2014-04-30

申请人： Hutchings, Nigel Wayne

发明人： Hutchings, Nigel Wayne

IPC分类号： A61M21/00

CPC分类号： A61M21/00 ,  A61M21/0094 ,  A61M2021/0005 ,  A61M2021/0022 ,  A61M2021/0027 ,  A61M2021/0044 ,  A61M2021/0066

摘要： Described herein is an apparatus comprising (i) one or more vibration means; (ii) a support for supporting the body of a subject, wherein the one or more vibration means and the support are positioned and configured such that, in use, when a subject is positioned on the support vibrations are transmittable from the vibration means through the support and to the subject; (iii) a light emitting means for providing a visually relaxing experience to a subject positioned on the support; (iv) a sound emitting means for providing an aurally relaxing experience to a subject positioned on the support; (v) a media device; (vi) a control means for coordinating emission of light patterns from the light emitting unit, sound from the sound emitting unit and vibrations from the vibration means with output from the media device; and (vii) an input for a microphone for allowing a user to speak to the subject via the sound emitting means.

摘要翻译： 这里描述的是一种装置，包括：（i）一个或多个振动装置; （ii）用于支撑被检体的支撑件，其中所述一个或多个振动装置和所述支撑件定位和构造成使得在使用时，当被检体位于所述支撑件上时，所述振动可通过所述振动装置传播 支持和主题; （iii）用于向位于所述支撑体上的被摄体提供视觉上轻松的体验的发光装置; （iv）发声装置，用于向位于支架上的被摄体提供听觉放松体验; （v）媒体设备; （vi）用于协调来自发光单元的光图案的发射，来自发音单元的声音和来自所述介质设备的输出的来自所述振动装置的振动的控制装置; 和（vii）用于允许用户经由声音发射装置与被摄体通话的麦克风的输入。

公开(公告)号：EP2750690A1

公开(公告)日：2014-07-09

申请号：EP12850386.9

申请日：2012-11-15

申请人： The Walter and Eliza Hall Institute of Medical Research

发明人： BANDALA SANCHEZ, Esther ,  DROMEY, James ,  HARRISON, Leonard Charles ,  ZHANG, Yuxia ,  RASHIDI, Maryam

IPC分类号： A61K38/10 ,  A61K38/28 ,  C12N15/12 ,  C12N15/86 ,  G01N33/15 ,  A61P5/50 ,  A61P37/06

CPC分类号： A61K38/177 ,  A61K38/10 ,  A61K47/68 ,  A61K48/00 ,  C07K14/70592 ,  C07K16/18 ,  C07K2319/30 ,  C12N5/0637 ,  C12Q1/6883 ,  G01N33/505 ,  G01N33/6872

摘要： The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.

摘要翻译： 本公开涉及可溶性CD52糖蛋白及其在治疗由效应T细胞调节的疾病中的应用，所述疾病例如自身免疫疾病如1型糖尿病。 本公开还涉及包含可溶性糖蛋白，表达高水平CD52的细胞的融合蛋白，以及基于检测受试者中CD52表达水平的诊断方法。

公开(公告)号：EP2714888A2

公开(公告)日：2014-04-09

申请号：EP12727897.6

申请日：2012-05-24

申请人： Chyna Llc ,  Armstrong, Michael, Norman

发明人： CONNOR, James, R. ,  KEIL, Ralph Lauren

IPC分类号： C12N1/19 ,  C07K14/47 ,  A61K38/17 ,  A61P25/28 ,  A61K9/127 ,  A61K47/42

CPC分类号： A61K45/06 ,  A61K33/26 ,  A61K38/1709 ,  C07K14/47 ,  C07K16/18 ,  A61K2300/00

摘要： Described are recombinant yeast comprising a nucleic acid sequence encoding human H-ferritin under the control of the yeast constitutive TDH3 transcriptional promoter, recombinant yeast comprising a nucleic acid sequence encoding human H- ferritin integrated into the yeast chromosome at the TDH3 site, H-ferritin expression cassettes for S. cerevisiae expressing human H-ferritin under the control of the yeast constitutive TDH3 transcriptional promoter, compositions comprising the recombinant yeast and their use in therapy, for example the treatment of iron disorders.

摘要翻译： 提出了用于治疗患者中铁紊乱的方法和组合物，包括将治疗有效量的铁递送至脑的方法。 可能通过这些方法治疗的铁疾病包括缺铁障碍和铁超负荷障碍。 还提供了表达人H-铁蛋白的重组酵母和用于治疗包含该重组酵母的铁病症的组合物。

公开(公告)号：EP2683236A1

公开(公告)日：2014-01-15

申请号：EP12710991.6

申请日：2012-03-07

申请人： Rothamsted Research Limited ,  Endura S.p.A.

发明人： MOORES, Graham David ,  PHILIPPOU, Despina ,  BORZATTA, Valerio ,  CAPPARELLA, Elisa

IPC分类号： A01N25/22 ,  A01N43/40 ,  A01N47/40 ,  A01N51/00 ,  A01P7/00

CPC分类号： A01N43/50 ,  A01N43/30 ,  A01N51/00 ,  A01N43/40 ,  A01N47/40 ,  A01N2300/00 ,  A01N31/04 ,  A01N31/16 ,  A01N43/12

摘要： Provided are compositions comprising (i) a neonicotinoid; and (ii) a compound of formula (I) or (II), preferably wherein the composition is a pesticide composition, for example an insecticide composition. Also provided is use of a compound of formula (I) or (II) as a neonicotinoid synergist and use of a compound of formula (I) or (II) in combination with a neonicotinoid. Further provided are methods for controlling pests.

公开(公告)号：EP2675322A1

公开(公告)日：2013-12-25

申请号：EP12747683.6

申请日：2012-02-16

申请人： Gild, Keith

发明人： Gild, Keith

IPC分类号： A47B91/02 ,  A47B91/16 ,  A47B9/00

CPC分类号： A47B91/02

摘要： The invention provides a device for adjusting the effective length of a table leg. The device includes an upper and a lower member (10, 12, 14) that is rotatably associated with one another and are biased apart by spring means (20), the upper member (14) including a first downwardly directed ramp (22) spaced apart from a second ratchet ramps (24) associated with the lower member (12) by a wall. The upper member (10) includes one or more pawls (25) adapted to run in the channel between the ramps (22, 24), and including a formation adapted to engage the ratchet when the desired effective length of the leg plus device has been adjusted.